Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$AITX News: AITX's Subsidiary, Robotic Assistance Devices, Receives Multiple ROSA Order from Major US City Alliance
Detroit, Michigan, April 25, 2023 (GLOBE NEWSWIRE) -- Artificial Intelligence Technology Solutions, Inc., (the "Company") (OTCPK:AITX), a global leader in AI-driven security and productivity solutions along with its wholly owned subsidiary, Robotic Assistance Devices, Inc. (RAD), today announced that it has received an order for 4 ROSA security robots from a major US city's business alliance group.
The end-user client is a non-profit organization, based in one of the top 50 metropolitan areas in the US. The organization works to create a safer, cleaner environment for every person that lives, works, plays, or visits the metropolitan area's downtown district. The nonprofit's mission is to help attract residents, employers, and investment opportunities to the city.
The initial 4 ROSA security devices will be deployed throughout one of the downtown area's popular outdoor-seating restaurant districts. One of the popular features of ROSA is its programmable messaging, both visual and audible, that will be utilized in this deployment to help communicate with patrons. As an example, when the restaurants are about to close at the end of the evening the ROSAs will autonomously initiate a persuasive 'it's time to go home' message, while continuing their security and safety post orders.
"This initial ROSA deployment is expected to expand within the city, and scale throughout other major metro areas," said Troy McCanna. "We're talking about deploying as many as 100 ROSAs through this alliance alone." McCanna, who enjoyed a distinguished 23-year career with the FBI, joined RAD in early 2022 and now serves as RAD's Chief Security Officer.
The Company noted that the 4 ROSA units are expected to be deployed and activated in early June, 2023.
"Since our inception, we have been working to place RAD solutions throughout major cities across the country," stated Mark Folmer, CPP, FSyI, President of RAD. "This is an ideal deployment for ROSA, acting as a force-multiplier to the security that's in place now, while providing an extra layer of personal-touch, concierge services."
ROSA is a multiple award-winning, compact, self-contained, portable, security and communication solution that can be installed and activated in about 15 minutes. Like other RAD solutions, it only requires power as it includes all necessary communications hardware. ROSA's AI-driven security analytics include human, firearm, vehicle detection, license plate recognition, responsive digital signage and audio messaging, and complete integration with RAD's software suite notification and autonomous response library. Two-way communication is optimized for cellular, including live video from ROSA's dual high-resolution, full-color, always-on cameras. RAD has published three Case Studies detailing how ROSA has helped eliminate instances of theft, trespassing and loitering at car rental locations and construction sites across the country.
AITX, through its subsidiary, Robotic Assistance Devices, Inc. (RAD), is redefining the $25 billion (US) security and guarding services industry through its broad lineup of innovative, AI-driven Solutions-as-a-Service business model. RAD solutions are specifically designed to provide cost savings to businesses of between 35%-80% when compared to the industry's existing and costly manned security guarding and monitoring model. RAD delivers this tremendous cost savings via a suite of stationary and mobile robotic solutions that complement, and at times, directly replace the need for human personnel in environments better suited for machines. All RAD technologies, AI-based analytics and software platforms are developed in-house.
RAD has a prospective sales pipeline of over 35 Fortune 500 companies and numerous other client opportunities. RAD expects to continue to attract new business as it converts its existing sales opportunities into deployed clients generating a recurring revenue stream. Each Fortune 500 client has the potential of making numerous reorders over time.
CAUTIONARY DISCLOSURE ABOUT FORWARD-LOOKING STATEMENTS
The information contained in this publication does not constitute an offer to sell or solicit an offer to buy securities of Artificial Intelligence Technology Solutions, Inc. (the "Company"). This publication contains forward-looking statements, which are not guarantees of future performance and may involve subjective judgment and analysis. The information provided herein is believed to be accurate and reliable, however the Company makes no representations or warranties, expressed or implied, as to its accuracy or completeness. The Company has no obligation to provide the recipient with additional updated information. No information in this publication should be interpreted as any indication whatsoever of the Company's future revenues, results of operations, or stock price.
About Artificial Intelligence Technology Solutions (AITX)
AITX is an innovator in the delivery of artificial intelligence-based solutions that empower organizations to gain new insight, solve complex challenges and fuel new business ideas. Through its next-generation robotic product offerings, AITX's RAD, RAD-M and RAD-G companies help organizations streamline operations, increase ROI, and strengthen business. AITX technology improves the simplicity and economics of patrolling and guard services and allows experienced personnel to focus on more strategic tasks. Customers augment the capabilities of existing staff and gain higher levels of situational awareness, all at drastically reduced cost. AITX solutions are well suited for use in multiple industries such as enterprises, government, transportation, critical infrastructure, education, and healthcare. To learn more, visit http://www.aitx.ai, http://www.stevereinharz.com, http://www.radsecurity.com,http://www.radgroup.ai, and http://www.radlightmyway.com, or follow Steve Reinharz on Twitter @SteveReinharz.
###
Steve Reinharz
949-636-7060
@SteveReinharz
$SGTM Tony Raynor interviewed by Jane King at The New Your Stock Exchange (NYSE)
$EMED "Q4 was a breakout quarter. We saw topline sales jump in response to further expansion in our brand awareness and sales & marketing performance. Overall, it was our best quarter since we went public and provides strong market feedback that our next-generation R&D and market positioning represents the start of an exciting new chapter for Electromedical. And the path is only going to get more exciting as we get ready to launch our revolutionary Infinity device."
As the Company moves closer to production of the new next-generation flagship device, management plans to offer a special upgrade and exchange program to existing clients, which will be bundled with a lifetime warranty.
The WellnessPro Infinity™ sets a new standard in the bioelectronics and electrotherapy marketplace featuring support for all modalities:
Designed to support*: TENS, Microcurrent, IF, EMS, PEMF, CES, VNS, PNS, COLD Laser, POD Synchronization, IDNA™, Deep Pulse™, cloud access and much more.
Unprecedented accuracy.
Easiest to use electrotherapy device on the market.
New Doctor-Patient Portal for updates and personalized treatments.
Wolfson concluded, "Last year was an ambitious year focused on key R&D objectives that we have met and now we are laying a strong foundation for handling business at a far larger scale. We accomplished everything we set out to accomplish and managed to log impressive sales growth along the way. We are also in the process of expanding consumer resources for purchasing Electromedical products. We have added FSA/HSA purchasing optionality already, and we have some more news coming that could sharply increase customer affordability without impacting our margins, and we look forward to discussing that in further detail very soon."
Management notes that 2023 will see the launch of the WellnessPro Infinity™, continued expansion in its sales team, a strong focus on value-add strategic partnerships, research partnerships and further customer affordability strategies as the Company monetizes its market-leading next-generation drug-free pain therapy technology.
The Company has approximately 10,000 past clients. We expect that we will be successful in encouraging a significant part of our past clients to exchange their old units for the improved Wellness Pro Infinity unit with lifetime warranty. Our development process is progressing and we look forward to providing more updates very soon. We will be in a position to start accepting advance deposits in Q2 for these units, which will greatly enhance the Company's cash position.
About Electromedical Technologies
Headquartered in Scottsdale, Arizona, Electromedical Technologies, Inc. is a commercial stage, FDA cleared, bioelectronic medical device manufacturing company initially focused on the treatment of various chronic, acute, intractable, and post-operative pain conditions. Through University collaboration agreements, the Company is working to develop a comprehensive research program in defining the effects of electro-modulation on the human body. By studying the impacts of electrical fields in cell signaling and effects on virus assembly and immune responses, the Company's goal is to reduce pain and improve overall human wellbeing. The Company's current FDA cleared product indications are for chronic acute post traumatic and post-operative, intractable pain relief.
For more information, please visit www.electromedtech.com
$EMED ("Electromedical" or the "Company"), a pioneer in the development and production of bioelectronic devices designed to relieve chronic, intractable, and acute pain through frequency and electro-modulation, is pleased to announce preliminary unaudited financial performance data for the three months and twelve months ended December 31, 2022.
Preliminary revenue for the twelve months ended Dec 31 was approximately $1.15 million, which represents a total increase in sales of 26.7% on a year-over-year basis.
During the three months ended Dec 31, preliminary revenue increased 79% on a quarterly year-over-year basis and 51% on a sequential quarterly basis.
Matthew Wolfson, Founder and CEO commented, "Q4 was a breakout quarter. We saw topline sales jump in response to further expansion in our brand awareness and sales & marketing performance. Overall, it was our best quarter since we went public and provides strong market feedback that our next-generation R&D and market positioning represents the start of an exciting new chapter for Electromedical. And the path is only going to get more exciting as we get ready to launch our revolutionary Infinity device."
As the Company moves closer to production of the new next-generation flagship device, management plans to offer a special upgrade and exchange program to existing clients, which will be bundled with a lifetime warranty.
The WellnessPro Infinity™ sets a new standard in the bioelectronics and electrotherapy marketplace featuring support for all modalities:
Designed to support*: TENS, Microcurrent, IF, EMS, PEMF, CES, VNS, PNS, COLD Laser, POD Synchronization, IDNA™, Deep Pulse™, cloud access and much more.
Unprecedented accuracy.
Easiest to use electrotherapy device on the market.
New Doctor-Patient Portal for updates and personalized treatments.
Wolfson concluded, "Last year was an ambitious year focused on key R&D objectives that we have met and now we are laying a strong foundation for handling business at a far larger scale. We accomplished everything we set out to accomplish and managed to log impressive sales growth along the way. We are also in the process of expanding consumer resources for purchasing Electromedical products. We have added FSA/HSA purchasing optionality already, and we have some more news coming that could sharply increase customer affordability without impacting our margins, and we look forward to discussing that in further detail very soon."
Management notes that 2023 will see the launch of the WellnessPro Infinity™, continued expansion in its sales team, a strong focus on value-add strategic partnerships, research partnerships and further customer affordability strategies as the Company monetizes its market-leading next-generation drug-free pain therapy technology.
The Company has approximately 10,000 past clients. We expect that we will be successful in encouraging a significant part of our past clients to exchange their old units for the improved Wellness Pro Infinity unit with lifetime warranty. Our development process is progressing and we look forward to providing more updates very soon. We will be in a position to start accepting advance deposits in Q2 for these units, which will greatly enhance the Company's cash position.
About Electromedical Technologies
Headquartered in Scottsdale, Arizona, Electromedical Technologies, Inc. is a commercial stage, FDA cleared, bioelectronic medical device manufacturing company initially focused on the treatment of various chronic, acute, intractable, and post-operative pain conditions. Through University collaboration agreements, the Company is working to develop a comprehensive research program in defining the effects of electro-modulation on the human body. By studying the impacts of electrical fields in cell signaling and effects on virus assembly and immune responses, the Company's goal is to reduce pain and improve overall human wellbeing. The Company's current FDA cleared product indications are for chronic acute post traumatic and post-operative, intractable pain relief.
For more information, please visit www.electromedtech.com
$EMED Preliminary revenue for the twelve months ended Dec 31 was approximately $1.15 million, which represents a total increase in sales of 26.7% on a year-over-year basis.
$EMED Preliminary revenue for the twelve months ended Dec 31 was approximately $1.15 million, which represents a total increase in sales of 26.7% on a year-over-year basis.
$CDSG SAMPLES UP TO 2.28% LI2O AT TITAN 2 PROJECT, TANZANIA
Las Vegas, NV., April 24, 2023 (GLOBE NEWSWIRE) -- Titan Lithium Inc., (OTC Markets: CDSG) (the "Company" or "CDSG") is pleased to announce new positive soil geochemical sample results from further sampling of the company's expansive Titan 2 lithium property in Tanzania.
The new results complete the approximately 3,950 acres (16 square kilometers) soil geochem sample grid for which the Company had previously reported partial results on March 19th 2023.
The expansive grid covers about 30% of the total Titan 2 project and was designed and conducted by the technical team to follow up on strong lithium geochemical results obtained from prospecting in the area.
With all of the soil sample results from the grid in, we note that positive Lithium geochemical values delineate a continuous zone that covers over half the grid area and averages 1.11% Li2O (4,486 ppm Lithium). The lowest positive value returned 200 ppm Li and the highest value returned 2.28% Li2O (10,600 ppm Li).
The Titan 2 project is located approximately 20 miles west of the larger Titan 1 claim group and, through a new interpretation of airborne magnetic data, appears to be wholly contained within a northeast-southwest-striking fault-bounded structure that may have served to trap Lithium-rich source volcanics and sediments.
Presently the Titan 2 lithium anomaly, which encompasses 2,090 acres and grades 4,486 ppm lithium, compares very favorably to the area of the Thacker Pass mine pit, which covers 1,093 acres and contains 40 years of reserves with an average grade of 3,160 ppm Li.
Craig Alford, MSc, PGeo, and CEO of the Company, a Qualified Person under NI 43-101, noted "The surficial results from Titan 2 are exceptional and have helped both expand and define a significant area of very strong lithium in this region. Follow up work will include further prospecting, geologic mapping, infill sampling and a drill program when permitted."
All samples were collected and transported to the laboratory under the direct supervision of a qualified person. The soil samples were recovered from the B-soil horizon and placed in cloth sample bags. The samples were thoroughly dried at 60oC during preparation and analyzed at the independent ISO 9001 certified African Minerals and Geosciences Centre (AMGC) in Dar es Salaam.
About the Company: China Dongsheng International Inc. (OTC Markets: CDSG), through its wholly owned subsidiary Titan Lithium, Inc., is a lithium explorer and developer with operations in Nevada, USA and The United Republic of Tanzania.
Contact:
Harp Sangha-Chairman
harp@titanlithiuminc.com
+1-702-595-2247
http://www.titanlithiuminc.com
Forward-Looking Statements:
This press release may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to financial results and plans for future development activities and are thus prospective. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company's ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are risks and uncertainties associated with the Company's business and finances in general, including the ability to continue and manage its growth, competition, global economic conditions and other factors discussed in detail in the Company's periodic filings with the Securities and Exchange Commission.
$SGTM Upgrades its Mulch Colorant Division to a Larger State of the Art Facility to Increase Production Due to Increase Demand https://finance.yahoo.com/news/sustainable-green-team-ltd-upgrades-132400465.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr via @YahooFinance
$EMED Electromedical Technologies, Inc. (OTC-QB: EMED) ("Electromedical" or the "Company"), a pioneer in the development and production of bioelectronic devices designed to relieve chronic, intractable, and acute pain through frequency and electro-modulation, is pleased to announce preliminary unaudited financial performance data for the three months and twelve months ended December 31, 2022.
Preliminary revenue for the twelve months ended Dec 31 was approximately $1.15 million, which represents a total increase in sales of 26.7% on a year-over-year basis.
During the three months ended Dec 31, preliminary revenue increased 79% on a quarterly year-over-year basis and 51% on a sequential quarterly basis.
Matthew Wolfson, Founder and CEO commented, "Q4 was a breakout quarter. We saw topline sales jump in response to further expansion in our brand awareness and sales & marketing performance. Overall, it was our best quarter since we went public and provides strong market feedback that our next-generation R&D and market positioning represents the start of an exciting new chapter for Electromedical. And the path is only going to get more exciting as we get ready to launch our revolutionary Infinity device."
As the Company moves closer to production of the new next-generation flagship device, management plans to offer a special upgrade and exchange program to existing clients, which will be bundled with a lifetime warranty.
The WellnessPro Infinity™ sets a new standard in the bioelectronics and electrotherapy marketplace featuring support for all modalities:
Designed to support*: TENS, Microcurrent, IF, EMS, PEMF, CES, VNS, PNS, COLD Laser, POD Synchronization, IDNA™, Deep Pulse™, cloud access and much more.
Unprecedented accuracy.
Easiest to use electrotherapy device on the market.
New Doctor-Patient Portal for updates and personalized treatments.
Wolfson concluded, "Last year was an ambitious year focused on key R&D objectives that we have met and now we are laying a strong foundation for handling business at a far larger scale. We accomplished everything we set out to accomplish and managed to log impressive sales growth along the way. We are also in the process of expanding consumer resources for purchasing Electromedical products. We have added FSA/HSA purchasing optionality already, and we have some more news coming that could sharply increase customer affordability without impacting our margins, and we look forward to discussing that in further detail very soon."
Management notes that 2023 will see the launch of the WellnessPro Infinity™, continued expansion in its sales team, a strong focus on value-add strategic partnerships, research partnerships and further customer affordability strategies as the Company monetizes its market-leading next-generation drug-free pain therapy technology.
The Company has approximately 10,000 past clients. We expect that we will be successful in encouraging a significant part of our past clients to exchange their old units for the improved Wellness Pro Infinity unit with lifetime warranty. Our development process is progressing and we look forward to providing more updates very soon. We will be in a position to start accepting advance deposits in Q2 for these units, which will greatly enhance the Company's cash position.
About Electromedical Technologies
Headquartered in Scottsdale, Arizona, Electromedical Technologies, Inc. is a commercial stage, FDA cleared, bioelectronic medical device manufacturing company initially focused on the treatment of various chronic, acute, intractable, and post-operative pain conditions. Through University collaboration agreements, the Company is working to develop a comprehensive research program in defining the effects of electro-modulation on the human body. By studying the impacts of electrical fields in cell signaling and effects on virus assembly and immune responses, the Company's goal is to reduce pain and improve overall human wellbeing. The Company's current FDA cleared product indications are for chronic acute post traumatic and post-operative, intractable pain relief.
For more information, please visit www.electromedtech.com
$EMED Electricity enables information to circulate in the body, electrotherapy manipulates a specific part of the information by pulsating electrical waves interfering with the transmission of pain signals.
Our nervous system is composed of our brain and our spinal cord, which combine to form the central nervous system; and our sensory and motor nerves, which form the peripheral nervous system. Nerves send information about what is happening in our environment to the brain via the spinal cord. The brain then sends information back to our nerves, helping us to perform actions in response. By treating specific body areas and varying frequency, wavelength and intensity applied, electrotherapy devices can manipulate impulses and target actions to alleviate pain or they can disrupt pain signals.
$EMED Electrotherapy is a nerve stimulation therapy via carefully developed electrical impulses mimicking our
body signals to help restore damages caused by injuries or accidents.
Significant percentage of patients found TENS devices effectively reduced their pain.
https://electromedtech.com/electrotherapy-explained/
$IDEX 12-month price forecasts for Ideanomics Inc have a median target of 1.00, with a high estimate of 1.00 and a low estimate of 1.00. The median estimate represents a +2,470.69% increase from the last price of 0.04.
$SMME News: SmartMetric Welcomes The Announced End Of The Credit Card Mag Stripe With It Being Replaced By Fingerprint Biometric Cards
Press Release | 04/21/2023
SmartMetric, Inc. (OTC: SMME) – It is reported that Spain is the first European country that has officially announced the adoption of fingerprint activated biometric credit and debit cards that will not have a mag stripe.
Because of the inherit risk of mag stripes that are easily read and copied, Spain is being reported that card issuing banks will stop using magnetic stripes on their cards and replacing existing credit cards with fingerprint biometrics only cards.
“We have been waiting a long time for this to happen and we are delighted that the banking world is now moving to adopt biometric only credit cards," said SmartMetric’s President & CEO, Chaya Hendrick.
SmartMetric is well positioned to capitalize on this revolutionary change in the banking credit card industry. Having just announced the assembly of its new biometric card that incorporates the company's latest advancements such as hardware based live fingerprint detection on the card as well as an advanced green hybrid nano rechargeable battery inside the card.
SmartMetric has developed the most advanced fingerprint activated biometric credit card in the world and is well positioned to capitalize on what is more than an 11 billion cards global market.
SmartMetric has literally spent years in research and development to miniaturize the electronics of biometric fingerprint capture, similar to that used in smartphones, to the thickness of less than a quarter thickness of a standard credit card.
The SmartMetric biometric fingerprint activated card is compatible with all existing credit card readers and ATM’s. Since it has its own internal green hybrid green nano battery it works with readers that take into the reader the card such as at ATMs and most new chip card reading gas pumps.
According to figures released by the credit card industry standards body more than 11 billion chip cards have now been issued by financial institutions around the world. The SmartMetric biometric fingerprint inside the card technology works with chip cards.
ABOUT THE SMARTMETRIC BIOMETRIC CARD: Keeping your biometric identity safe is at the center of the design of the SmartMetric biometric card. At no time does a card holder's fingerprint leave the card. A person’s fingerprint is stored inside the card and matching of the person's fingerprint is done on the card itself. This was a central design requirement of the SmartMetric biometric card solution that necessitated SmartMetric to create a self-powered inside the card, fully functional fingerprint scanner. Also, so that the card could be used at ATMs and POS (Point Of Sale) card readers the SmartMetric development team created an on card miniature power management system that recharges the card as it is being used in card readers.
To view the SmartMetric Biometric Card please follow this link - Video of the SmartMetric Biometric Card
To view the company website: http://www.smartmetric.com
Spain moves to adopt biometric only credit cards: This Is The Change That Will Be Announced By Our Credit Card Banks (worldnationnews.com)
Safe Harbor Statement: Forward-Looking Statements in this press release, which are not historical facts, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Also such forward-looking statements are within the meaning of that term in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Our actual results, performance or achievements may differ materially from those expressed or implied by these forward-looking statements. In some cases, you can identify forward-looking statements by the use of words such as "may," "could," "expect," "intend," "plan," "seek," "anticipate," "believe," "estimate," "predict," "potential," "continue," "likely," "will," "would" and variations of these terms and similar expressions, or the negative of these terms or similar expressions. Such forward-looking statements are necessarily based upon estimates and assumptions that, while considered reasonable by us and our management, are inherently uncertain. Factors that may cause actual results to differ materially from current expectations include, among others, if we are unable to access the capital necessary to fund current operations or implement our plans for growth; changes in the competitive environment in our industry and the markets where we operate; our ability to access the capital markets; and other risks discussed in the Company's filings with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10-K, which filings are available from the SEC. We caution you not to place undue reliance on any forward-looking statements, which are made as of the date of this press release. We undertake no obligation to update publicly any of these forward-looking statements to reflect actual results, new information or future events, changes in assumptions or changes in other factors affecting forward-looking statements, except to the extent required by applicable laws. If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements.
Investors and security holders are urged to carefully review and consider each of SmartMetric Inc. public filings with the SEC, including but not limited to, if applicable, Annual Reports on Form 10-K, proxy statements, Current Reports on Form 8-K and Quarterly Reports on Form 10-Q.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230421005114/en/
$EMED Electromedical Technologies, Inc. (OTC-QB: EMED) ("Electromedical" or the "Company"), a pioneer in the development and production of bioelectronic devices designed to relieve chronic, intractable, and acute pain through frequency and electro-modulation, is pleased to announce preliminary unaudited financial performance data for the three months and twelve months ended December 31, 2022.
Preliminary revenue for the twelve months ended Dec 31 was approximately $1.15 million, which represents a total increase in sales of 26.7% on a year-over-year basis.
During the three months ended Dec 31, preliminary revenue increased 79% on a quarterly year-over-year basis and 51% on a sequential quarterly basis.
Matthew Wolfson, Founder and CEO commented, "Q4 was a breakout quarter. We saw topline sales jump in response to further expansion in our brand awareness and sales & marketing performance. Overall, it was our best quarter since we went public and provides strong market feedback that our next-generation R&D and market positioning represents the start of an exciting new chapter for Electromedical. And the path is only going to get more exciting as we get ready to launch our revolutionary Infinity device."
As the Company moves closer to production of the new next-generation flagship device, management plans to offer a special upgrade and exchange program to existing clients, which will be bundled with a lifetime warranty.
The WellnessPro Infinity™ sets a new standard in the bioelectronics and electrotherapy marketplace featuring support for all modalities:
Designed to support*: TENS, Microcurrent, IF, EMS, PEMF, CES, VNS, PNS, COLD Laser, POD Synchronization, IDNA™, Deep Pulse™, cloud access and much more.
Unprecedented accuracy.
Easiest to use electrotherapy device on the market.
New Doctor-Patient Portal for updates and personalized treatments.
Wolfson concluded, "Last year was an ambitious year focused on key R&D objectives that we have met and now we are laying a strong foundation for handling business at a far larger scale. We accomplished everything we set out to accomplish and managed to log impressive sales growth along the way. We are also in the process of expanding consumer resources for purchasing Electromedical products. We have added FSA/HSA purchasing optionality already, and we have some more news coming that could sharply increase customer affordability without impacting our margins, and we look forward to discussing that in further detail very soon."
Management notes that 2023 will see the launch of the WellnessPro Infinity™, continued expansion in its sales team, a strong focus on value-add strategic partnerships, research partnerships and further customer affordability strategies as the Company monetizes its market-leading next-generation drug-free pain therapy technology.
The Company has approximately 10,000 past clients. We expect that we will be successful in encouraging a significant part of our past clients to exchange their old units for the improved Wellness Pro Infinity unit with lifetime warranty. Our development process is progressing and we look forward to providing more updates very soon. We will be in a position to start accepting advance deposits in Q2 for these units, which will greatly enhance the Company's cash position.
About Electromedical Technologies
Headquartered in Scottsdale, Arizona, Electromedical Technologies, Inc. is a commercial stage, FDA cleared, bioelectronic medical device manufacturing company initially focused on the treatment of various chronic, acute, intractable, and post-operative pain conditions. Through University collaboration agreements, the Company is working to develop a comprehensive research program in defining the effects of electro-modulation on the human body. By studying the impacts of electrical fields in cell signaling and effects on virus assembly and immune responses, the Company's goal is to reduce pain and improve overall human wellbeing. The Company's current FDA cleared product indications are for chronic acute post traumatic and post-operative, intractable pain relief.
For more information, please visit www.electromedtech.com
$EMED Management notes that 2023 will see the launch of the WellnessPro Infinity™, continued expansion in its sales team, a strong focus on value-add strategic partnerships, research partnerships and further customer affordability strategies as the Company monetizes its market-leading next-generation drug-free pain therapy technology.
$EMED The Company has approximately 10,000 past clients. We expect that we will be successful in encouraging a significant part of our past clients to exchange their old units for the improved Wellness Pro Infinity unit with lifetime warranty. Our development process is progressing and we look forward to providing more updates very soon. We will be in a position to start accepting advance deposits in Q2 for these units, which will greatly enhance the Company's cash position.
$EMED As the Company moves closer to production of the new next-generation flagship device, management plans to offer a special upgrade and exchange program to existing clients, which will be bundled with a lifetime warranty.
$EMED Matthew Wolfson, Founder and CEO commented, "Q4 was a breakout quarter. We saw topline sales jump in response to further expansion in our brand awareness and sales & marketing performance. Overall, it was our best quarter since we went public and provides strong market feedback that our next-generation R&D and market positioning represents the start of an exciting new chapter for Electromedical. And the path is only going to get more exciting as we get ready to launch our revolutionary Infinity device."
$EMED "Q4 was a breakout quarter. We saw topline sales jump in response to further expansion in our brand awareness and sales & marketing performance. Overall, it was our best quarter since we went public and provides strong market feedback that our next-generation R&D and market positioning represents the start of an exciting new chapter for Electromedical. And the path is only going to get more exciting as we get ready to launch our revolutionary Infinity device."
As the Company moves closer to production of the new next-generation flagship device, management plans to offer a special upgrade and exchange program to existing clients, which will be bundled with a lifetime warranty.
The WellnessPro Infinity™ sets a new standard in the bioelectronics and electrotherapy marketplace featuring support for all modalities:
Designed to support*: TENS, Microcurrent, IF, EMS, PEMF, CES, VNS, PNS, COLD Laser, POD Synchronization, IDNA™, Deep Pulse™, cloud access and much more.
Unprecedented accuracy.
Easiest to use electrotherapy device on the market.
New Doctor-Patient Portal for updates and personalized treatments.
Wolfson concluded, "Last year was an ambitious year focused on key R&D objectives that we have met and now we are laying a strong foundation for handling business at a far larger scale. We accomplished everything we set out to accomplish and managed to log impressive sales growth along the way. We are also in the process of expanding consumer resources for purchasing Electromedical products. We have added FSA/HSA purchasing optionality already, and we have some more news coming that could sharply increase customer affordability without impacting our margins, and we look forward to discussing that in further detail very soon."
Management notes that 2023 will see the launch of the WellnessPro Infinity™, continued expansion in its sales team, a strong focus on value-add strategic partnerships, research partnerships and further customer affordability strategies as the Company monetizes its market-leading next-generation drug-free pain therapy technology.
The Company has approximately 10,000 past clients. We expect that we will be successful in encouraging a significant part of our past clients to exchange their old units for the improved Wellness Pro Infinity unit with lifetime warranty. Our development process is progressing and we look forward to providing more updates very soon. We will be in a position to start accepting advance deposits in Q2 for these units, which will greatly enhance the Company's cash position.
About Electromedical Technologies
Headquartered in Scottsdale, Arizona, Electromedical Technologies, Inc. is a commercial stage, FDA cleared, bioelectronic medical device manufacturing company initially focused on the treatment of various chronic, acute, intractable, and post-operative pain conditions. Through University collaboration agreements, the Company is working to develop a comprehensive research program in defining the effects of electro-modulation on the human body. By studying the impacts of electrical fields in cell signaling and effects on virus assembly and immune responses, the Company's goal is to reduce pain and improve overall human wellbeing. The Company's current FDA cleared product indications are for chronic acute post traumatic and post-operative, intractable pain relief.
For more information, please visit www.electromedtech.com
$EMED a pioneer in the development and production of bioelectronic devices designed to relieve chronic, intractable, and acute pain through frequency and electro-modulation, is pleased to announce preliminary unaudited financial performance data for the three months and twelve months ended December 31, 2022.
Preliminary revenue for the twelve months ended Dec 31 was approximately $1.15 million, which represents a total increase in sales of 26.7% on a year-over-year basis.
During the three months ended Dec 31, preliminary revenue increased 79% on a quarterly year-over-year basis and 51% on a sequential quarterly basis.
Matthew Wolfson, Founder and CEO commented, "Q4 was a breakout quarter. We saw topline sales jump in response to further expansion in our brand awareness and sales & marketing performance. Overall, it was our best quarter since we went public and provides strong market feedback that our next-generation R&D and market positioning represents the start of an exciting new chapter for Electromedical. And the path is only going to get more exciting as we get ready to launch our revolutionary Infinity device."
As the Company moves closer to production of the new next-generation flagship device, management plans to offer a special upgrade and exchange program to existing clients, which will be bundled with a lifetime warranty.
The WellnessPro Infinity™ sets a new standard in the bioelectronics and electrotherapy marketplace featuring support for all modalities:
Designed to support*: TENS, Microcurrent, IF, EMS, PEMF, CES, VNS, PNS, COLD Laser, POD Synchronization, IDNA™, Deep Pulse™, cloud access and much more.
Unprecedented accuracy.
Easiest to use electrotherapy device on the market.
New Doctor-Patient Portal for updates and personalized treatments.
Wolfson concluded, "Last year was an ambitious year focused on key R&D objectives that we have met and now we are laying a strong foundation for handling business at a far larger scale. We accomplished everything we set out to accomplish and managed to log impressive sales growth along the way. We are also in the process of expanding consumer resources for purchasing Electromedical products. We have added FSA/HSA purchasing optionality already, and we have some more news coming that could sharply increase customer affordability without impacting our margins, and we look forward to discussing that in further detail very soon."
Management notes that 2023 will see the launch of the WellnessPro Infinity™, continued expansion in its sales team, a strong focus on value-add strategic partnerships, research partnerships and further customer affordability strategies as the Company monetizes its market-leading next-generation drug-free pain therapy technology.
The Company has approximately 10,000 past clients. We expect that we will be successful in encouraging a significant part of our past clients to exchange their old units for the improved Wellness Pro Infinity unit with lifetime warranty. Our development process is progressing and we look forward to providing more updates very soon. We will be in a position to start accepting advance deposits in Q2 for these units, which will greatly enhance the Company's cash position.
About Electromedical Technologies
Headquartered in Scottsdale, Arizona, Electromedical Technologies, Inc. is a commercial stage, FDA cleared, bioelectronic medical device manufacturing company initially focused on the treatment of various chronic, acute, intractable, and post-operative pain conditions. Through University collaboration agreements, the Company is working to develop a comprehensive research program in defining the effects of electro-modulation on the human body. By studying the impacts of electrical fields in cell signaling and effects on virus assembly and immune responses, the Company's goal is to reduce pain and improve overall human wellbeing. The Company's current FDA cleared product indications are for chronic acute post traumatic and post-operative, intractable pain relief.
For more information, please visit www.electromedtech.com
$EMED Announces Preliminary Unaudited Revenue for Q4 and FY 2022 and update on operations https://finance.yahoo.com/news/electromedical-technologies-announces-preliminary-unaudited-121900011.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr via @YahooFinance
$EMED Electrotherapy is a nerve stimulation therapy via carefully developed electrical impulses mimicking our
body signals to help restore damages caused by injuries or accidents.
Significant percentage of patients found TENS devices effectively reduced their pain.
https://electromedtech.com/electrotherapy-explained/
$SBIG News: springbig Introduces Brands Marketplace Feature
springbig's first artificial intelligence feature helps retailers make data-driven decisions
BOCA RATON, Fla., April 19, 2023 (GLOBE NEWSWIRE) -- springbig (the "Company") (NASDAQ: SBIG), a leading provider of SaaS-based marketing solutions, today announced the launch of its Brands Marketplace Offering. The Company's first artificial intelligence-based ("AI") solution uses consumer data to help its retail clients make data-driven decisions regarding the brands and products that are offered in their place of business.
springbig designed the Brands Marketplace to enhance the cannabis retail experience for retailers and consumers. The Company's data-driven solution tracks pertinent consumer trends within each of its Retail Clients including time of purchase, types of products purchased and the frequency at which customers buy particular items from said Retailer. Using advanced machine learning algorithms, the Brands Marketplace analyzes a customer's shopping habits and identifies patterns in their behavior, preferences and demographics. Retailers can utilize the trends identified by the Brands Marketplace to make better-informed decisions regarding the brands that will be offered in their stores. The Company believes this will in turn yield the greatest return for the retailer and at the same time provide their consumers with the most appropriate product selection
"We are thrilled to introduce our first AI offering, which enables store owners to keep up with the different consumer trends developing day to day," said Jeffrey Harris, CEO of springbig. "Numerous consumers can regularly cycle through a storefront and purchase dozens of different items, which can be difficult for store owners to track. Fortunately, our new tool will simplify this aspect of business for our clients and help them make decisions that will benefit them and their patrons alike."
The Brands Marketplace is the latest addition to springbig's suite of business solutions. This year, the Company has launched its Build Your Own Audience, Compare Campaigns, Member Offers, Campaign Caddie and Email Marketing Engines features. Additionally, springbig has introduced integrations with COMBASE, Alleaves and Flowhub. The Company's collection of data-driven tools has garnered recognition by Deloitte Fast 500, South Florida Business Journal Miami Inno Fire Awards, and more. For more information regarding springbig's latest efforts, please visit https://springbig.com/.
About springbig
springbig is a market-leading software platform providing customer loyalty and marketing automation solutions to cannabis retailers and brands in the U.S. and Canada. springbig's platform connects consumers with retailers and brands, primarily through SMS marketing, as well as emails, customer feedback system, and loyalty programs, to support retailers' and brands' customer engagement and retention. springbig offers marketing automation solutions that provide for consistency of customer communication, thereby driving customer retention and retail foot traffic. Additionally, springbig's reporting and analytics offerings deliver valuable insights that clients utilize to better understand their customer base, purchasing habits and trends. For more information, visit https://springbig.com/.
Forward Looking Statements
Certain statements contained in this press release constitute "forward-looking statements" within the meaning of federal securities laws. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intends," "outlook," "may," "might," "plan," "possible," "potential," "predict," "project," "should," "would," and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to the risks and uncertainties described under "Risk Factors" 'in the Company's Annual Report on Form 10-K for the year ended December 31, 2022 filed with the Securities and Exchange Commission (the "SEC") on March 28, 2023. These forward-looking statements involve a number of risks and uncertainties (some of which are beyond the control of springbig), and other assumptions, which may cause the actual results or performance to be materially different from those expressed or implied by these forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and the Company assumes no obligation and does not intend to update or revise these forward-looking statements other than as required by applicable law. The Company does not give any assurance that it will achieve its expectations.
Investor Relations Contact
Ryan Flanagan
ICR Strategic Communications & Advisory
ir@springbig.com
Media Contact
MATTIO Communications
Phoebe Wilson
springbig@mattio.com
$EMED during the three months ended Dec 31, preliminary revenue increased 79% on a quarterly year-over-year basis and 51% on a sequential quarterly basis.
Matthew Wolfson, Founder and CEO commented, "Q4 was a breakout quarter. We saw topline sales jump in response to further expansion in our brand awareness and sales & marketing performance. Overall, it was our best quarter since we went public and provides strong market feedback that our next-generation R&D and market positioning represents the start of an exciting new chapter for Electromedical. And the path is only going to get more exciting as we get ready to launch our revolutionary Infinity device."
As the Company moves closer to production of the new next-generation flagship device, management plans to offer a special upgrade and exchange program to existing clients, which will be bundled with a lifetime warranty.
The WellnessPro Infinity™ sets a new standard in the bioelectronics and electrotherapy marketplace featuring support for all modalities:
Designed to support*: TENS, Microcurrent, IF, EMS, PEMF, CES, VNS, PNS, COLD Laser, POD Synchronization, IDNA™, Deep Pulse™, cloud access and much more.
Unprecedented accuracy.
Easiest to use electrotherapy device on the market.
New Doctor-Patient Portal for updates and personalized treatments.
Wolfson concluded, "Last year was an ambitious year focused on key R&D objectives that we have met and now we are laying a strong foundation for handling business at a far larger scale. We accomplished everything we set out to accomplish and managed to log impressive sales growth along the way. We are also in the process of expanding consumer resources for purchasing Electromedical products. We have added FSA/HSA purchasing optionality already, and we have some more news coming that could sharply increase customer affordability without impacting our margins, and we look forward to discussing that in further detail very soon."
Management notes that 2023 will see the launch of the WellnessPro Infinity™, continued expansion in its sales team, a strong focus on value-add strategic partnerships, research partnerships and further customer affordability strategies as the Company monetizes its market-leading next-generation drug-free pain therapy technology.
The Company has approximately 10,000 past clients. We expect that we will be successful in encouraging a significant part of our past clients to exchange their old units for the improved Wellness Pro Infinity unit with lifetime warranty. Our development process is progressing and we look forward to providing more updates very soon. We will be in a position to start accepting advance deposits in Q2 for these units, which will greatly enhance the Company's cash position.
About Electromedical Technologies
Headquartered in Scottsdale, Arizona, Electromedical Technologies, Inc. is a commercial stage, FDA cleared, bioelectronic medical device manufacturing company initially focused on the treatment of various chronic, acute, intractable, and post-operative pain conditions. Through University collaboration agreements, the Company is working to develop a comprehensive research program in defining the effects of electro-modulation on the human body. By studying the impacts of electrical fields in cell signaling and effects on virus assembly and immune responses, the Company's goal is to reduce pain and improve overall human wellbeing. The Company's current FDA cleared product indications are for chronic acute post traumatic and post-operative, intractable pain relief.
For more information, please visit www.electromedtech.com
$EMED When it comes to electricity created in the human body, the energy source is chemical and has to do with the composition of the atoms and molecules present. All the elements we take into our bodies, such as oxygen, sodium, potassium, calcium, magnesium etc., have a specific electrical charge. How those molecules are bound together and how they react to other molecules near them is how chemicals create energy. Some of these electrical impulses found naturally in our bodies activate functions needed for healing.
$EMED Preliminary revenue for the twelve months ended Dec 31 was approximately $1.15 million, which represents a total increase in sales of 26.7% on a year-over-year basis.
$ASRE News: Astra Energy Inc. Executes Exclusive Sales, Marketing and Distribution Agreement in the Republic of India for the Regreen Waste-to-Energy Technology
SAN DIEGO, April 18, 2023 (GLOBE NEWSWIRE) -- via InvestorWire -- Astra Energy Inc. (OTCQB: ASRE) ("Astra" or the "Company"), is proud to announce an initial equipment sale and the formation of a joint venture with Astra Regreen India ("ARI"), an Indian corporation. ARI will hold exclusive rights for sales, marketing and distribution and establish a first-of-its-kind Municipal Recovery Waste Facility ("MRF") in the Southern States of the Republic of India.
Astra will receive a project deposit of $100,000 USD, an equipment deposit of $1,800,000 USD for the sale of the first 15 Ton Per Hour ("TPH") Regreen Total Waste System ("TWS"), and the balance first tier from operations. Upon successful implementation of the first installation, ARI is required to place orders for five more Regreen TWSs ranging between 3TPH to 15TPH capacity within 36 months. Additionally, Astra will hold a carried interest in the revenues of all future projects within the territory.
The "India Green Project" will consist of constructing a 30,000-square-foot facility at a designated landfill that will initially host a 15TPH Regreen TWS to process a minimum of 300 tons of municipal solid waste and agricultural waste per day. The landfill will provide a 25-year concession on land and feedstock (MSW and agricultural waste). Once processed through the Regreen TWS, the output will consist of low sulfur, bacteria and odor-free, high BTU and calorific-value energy pellets, as well as other valuable and marketable commodities to be sold in the global market. The first deployment will begin within six months.
"India has a huge challenge in the manner in which it must address its mammoth existing and ever-growing garbage problem. With the Regreen Total Waste System, we have the unique opportunity to solve this problem in a responsible way and have a truly positive impact on the environment," stated Anand Shanmugam, president of Astra Regreen India.
"Demonstrating the business case for the first MRF in the Republic of India that will divert 95% of its waste from the landfill is something Astra is looking forward to. India has the potential to be a huge and growing market for Astra and the Regreen Technology," stated Douglas D. Hampton, president and CEO of Astra Energy California, Inc. "We are fortunate to be dealing with entities and municipalities that are dedicated to a real positive impact on the environment and the betterment of the health and welfare of its people."
About Astra Regreen India Pvt Ltd.
The new entity Astra Regreen India Pvt Ltd. ("ARI"), based in Chennai, India, was formed to bring together an experienced group of successful businessmen with a track record of years of successful operations in the USA and India region. They will be focusing on advancing opportunities related to manufacturing and technology development within the clean and renewable sector. ARI has already made significant inroads with governmental entities in the Southern States of the Republic of India that are excited to see the implementation and success of the India Green Project.
About Astra Energy Inc.
Astra Energy Inc. is an integrated solutions provider investing in and developing renewable and clean energy projects in markets where demand is high, supply is limited and there is an opportunity to address other imminent market needs.
Astra's corporate strategy is rooted in securing technologies and assets; identifying viable market opportunities; and bringing together resources, expertise, technology and defined action plans to execute first-in-class projects that benefit communities, local economies, the planet and the Company's investors.
Its goal is to create a more secure and sustainable power sector that supports the Company's purpose, mission and values to transform the economic, environmental and social landscape for generations to come.
For more information on Astra Energy Inc., visit the Company's website at http://www.astraenergyinc.com.
CAUTIONARY STATEMENT CONCERNING FORWARD-LOOKING STATEMENTS
This document contains forward-looking statements. In evaluating these forward-looking statements, readers should consider various factors, including the Company's ability to change its direction, its ability to keep pace with new technology and changing market needs, and the competitive environment of its business. These and other factors may cause the Company's actual results to differ materially from any forward-looking statement.
Corporate Communications:
Heidi Thomasen
IR@astraenergyinc.com
1-800-705-2919
Wire Service Contact
InvestorWire (IW)
Los Angeles, California
www.InvestorWire.com
212.418.1217 Office
Editor@InvestorWire.com
$EMED Matthew Wolfson, Founder and CEO commented, "Q4 was a breakout quarter. We saw topline sales jump in response to further expansion in our brand awareness and sales & marketing performance. Overall, it was our best quarter since we went public and provides strong market feedback that our next-generation R&D and market positioning represents the start of an exciting new chapter for Electromedical. And the path is only going to get more exciting as we get ready to launch our revolutionary Infinity device."
As the Company moves closer to production of the new next-generation flagship device, management plans to offer a special upgrade and exchange program to existing clients, which will be bundled with a lifetime warranty.
The WellnessPro Infinity™ sets a new standard in the bioelectronics and electrotherapy marketplace featuring support for all modalities:
Designed to support*: TENS, Microcurrent, IF, EMS, PEMF, CES, VNS, PNS, COLD Laser, POD Synchronization, IDNA™, Deep Pulse™, cloud access and much more.
Unprecedented accuracy.
Easiest to use electrotherapy device on the market.
New Doctor-Patient Portal for updates and personalized treatments.
Wolfson concluded, "Last year was an ambitious year focused on key R&D objectives that we have met and now we are laying a strong foundation for handling business at a far larger scale. We accomplished everything we set out to accomplish and managed to log impressive sales growth along the way. We are also in the process of expanding consumer resources for purchasing Electromedical products. We have added FSA/HSA purchasing optionality already, and we have some more news coming that could sharply increase customer affordability without impacting our margins, and we look forward to discussing that in further detail very soon."
Management notes that 2023 will see the launch of the WellnessPro Infinity™, continued expansion in its sales team, a strong focus on value-add strategic partnerships, research partnerships and further customer affordability strategies as the Company monetizes its market-leading next-generation drug-free pain therapy technology.
The Company has approximately 10,000 past clients. We expect that we will be successful in encouraging a significant part of our past clients to exchange their old units for the improved Wellness Pro Infinity unit with lifetime warranty. Our development process is progressing and we look forward to providing more updates very soon. We will be in a position to start accepting advance deposits in Q2 for these units, which will greatly enhance the Company's cash position.
About Electromedical Technologies
Headquartered in Scottsdale, Arizona, Electromedical Technologies, Inc. is a commercial stage, FDA cleared, bioelectronic medical device manufacturing company initially focused on the treatment of various chronic, acute, intractable, and post-operative pain conditions. Through University collaboration agreements, the Company is working to develop a comprehensive research program in defining the effects of electro-modulation on the human body. By studying the impacts of electrical fields in cell signaling and effects on virus assembly and immune responses, the Company's goal is to reduce pain and improve overall human wellbeing. The Company's current FDA cleared product indications are for chronic acute post traumatic and post-operative, intractable pain relief.
For more information, please visit www.electromedtech.com
$EMED (OTC-QB: EMED) ("Electromedical" or the "Company"), a pioneer in the development and production of bioelectronic devices designed to relieve chronic, intractable, and acute pain through frequency and electro-modulation, is pleased to announce preliminary unaudited financial performance data for the three months and twelve months ended December 31, 2022.
Preliminary revenue for the twelve months ended Dec 31 was approximately $1.15 million, which represents a total increase in sales of 26.7% on a year-over-year basis.
During the three months ended Dec 31, preliminary revenue increased 79% on a quarterly year-over-year basis and 51% on a sequential quarterly basis.
Matthew Wolfson, Founder and CEO commented, "Q4 was a breakout quarter. We saw topline sales jump in response to further expansion in our brand awareness and sales & marketing performance. Overall, it was our best quarter since we went public and provides strong market feedback that our next-generation R&D and market positioning represents the start of an exciting new chapter for Electromedical. And the path is only going to get more exciting as we get ready to launch our revolutionary Infinity device."
As the Company moves closer to production of the new next-generation flagship device, management plans to offer a special upgrade and exchange program to existing clients, which will be bundled with a lifetime warranty.
The WellnessPro Infinity™ sets a new standard in the bioelectronics and electrotherapy marketplace featuring support for all modalities:
Designed to support*: TENS, Microcurrent, IF, EMS, PEMF, CES, VNS, PNS, COLD Laser, POD Synchronization, IDNA™, Deep Pulse™, cloud access and much more.
Unprecedented accuracy.
Easiest to use electrotherapy device on the market.
New Doctor-Patient Portal for updates and personalized treatments.
Wolfson concluded, "Last year was an ambitious year focused on key R&D objectives that we have met and now we are laying a strong foundation for handling business at a far larger scale. We accomplished everything we set out to accomplish and managed to log impressive sales growth along the way. We are also in the process of expanding consumer resources for purchasing Electromedical products. We have added FSA/HSA purchasing optionality already, and we have some more news coming that could sharply increase customer affordability without impacting our margins, and we look forward to discussing that in further detail very soon."
Management notes that 2023 will see the launch of the WellnessPro Infinity™, continued expansion in its sales team, a strong focus on value-add strategic partnerships, research partnerships and further customer affordability strategies as the Company monetizes its market-leading next-generation drug-free pain therapy technology.
The Company has approximately 10,000 past clients. We expect that we will be successful in encouraging a significant part of our past clients to exchange their old units for the improved Wellness Pro Infinity unit with lifetime warranty. Our development process is progressing and we look forward to providing more updates very soon. We will be in a position to start accepting advance deposits in Q2 for these units, which will greatly enhance the Company's cash position.
About Electromedical Technologies
Headquartered in Scottsdale, Arizona, Electromedical Technologies, Inc. is a commercial stage, FDA cleared, bioelectronic medical device manufacturing company initially focused on the treatment of various chronic, acute, intractable, and post-operative pain conditions. Through University collaboration agreements, the Company is working to develop a comprehensive research program in defining the effects of electro-modulation on the human body. By studying the impacts of electrical fields in cell signaling and effects on virus assembly and immune responses, the Company's goal is to reduce pain and improve overall human wellbeing. The Company's current FDA cleared product indications are for chronic acute post traumatic and post-operative, intractable pain relief.
For more information, please visit www.electromedtech.com
$EMED In 2018, 67,367 drug overdose deaths occurred in the United States, 70% of them involved opioids.
https://electromedtech.com/investors-relations/
$EMED Electrotherapy is a nerve stimulation therapy via carefully developed electrical impulses mimicking our
body signals to help restore damages caused by injuries or accidents.
Significant percentage of patients found TENS devices effectively reduced their pain.
https://electromedtech.com/electrotherapy-explained/
$EPAZ moving towards military contracts in the future! https://www.marketscreener.com/quote/stock/EPAZZ-INC-111313555/news/EPAZ-Moving-Towards-Future-Military-Contracts-43482729/
$OMHI News: Fourth OneMart Store Marks Milestone, OM Holdings International, Inc. Maintains Expansion Momentum and Outlines Future Plans
MIAMI, April 17, 2023 (GLOBE NEWSWIRE) -- OM Holdings International Inc (OTCQX: OMHI) proudly announces the recent opening of its third OneMart store in the last 9 months. The latest addition is the company's Lower Estate location, bringing the total to four of the popular OneMart stores now in operation. This milestone marks a significant step in the company's ongoing expansion, with each new store varying in size and amenities to serve as blueprints for future growth across three distinctly different market sizes. OMHI is also focusing on increasing revenues for the upcoming fiscal year as it continues to expand its retail footprint in the high consumer density Caribbean region.
OMHI is actively exploring the possibility of expanding its presence in other Caribbean islands and is currently analyzing acquisition targets to accelerate growth. As part of its strategic plan, the company is researching the implementation of three different sized Micro Fulfilment Centers (MFCs), tailored to match the size of its three previous stores. Some of these MFCs may function as Dark Stores, focusing exclusively on online orders, which enables faster order processing and delivery times for customers. With the upcoming launch of the DoMart experience on the DoGetGo App, OMHI is poised to transform the retail landscape in the region, offering customers an innovative and seamless shopping experience.
The OMHI Lower Estate store marks the fourth OneMart location, joining the existing Purcell Estate, Baughers Bay, and East End supermarkets. This new addition highlights the company's dedication to making shopping more convenient by strategically placing stores within people's communities. At the core of OMHI's mission is a customer-centric agenda, focused on the specific needs and desires of our customers. We aim to give them the freedom and power to shop according to their preferences, ultimately enhancing their overall shopping experience.
In support of OMHI public equity, the board of OM Holdings International Inc. is actively exploring options for up-listing to the Nasdaq and/or a secondary listing on the Toronto Stock Exchange's Venture Exchange (TSX-V) as part of its growth strategy. By pursuing these listings, the company aims to broaden its shareholder base and secure additional capital to fuel future expansion plans. This move demonstrates OM Holdings International Inc.'s commitment to creating value for its shareholders and enhancing its position as a leading omnichannel retail solution provider in the Caribbean region.
Mark Vanterpool, CEO and Chairman of OM Holdings International Inc., stated, "Our mission is to bring an omnichannel solution to the Caribbean, where customers have the flexibility to choose how they shop, whether through delivery, pick-up, or traditional in-store experiences. With our continued expansion and the upcoming launch of the DoMart experience on the DoGetGo App, we are poised to transform the retail landscape in the region."
The new OneMart stores serve as a testament to OMHI's commitment to providing customers with a seamless and convenient shopping experience. As the company continues its expansion in the upcoming calendar year, it aims to further its reach and cater to the diverse needs of the high value Caribbean market.
About OM Holdings International, Inc.
OM Holdings International, Inc. operates delivery services and grocery stores in the Caribbean, with a mobile application delivery platform that provides an expedient, contactless option for the transportation of people and essential goods. The company's storefront, OneMart, is the second-largest grocery store in the BVI. OHMI's delivery subsidiary, Rydeum, has partnered with Jamaica's largest taxicab union, JUTA. The company also provides lumber and other construction supplies to contractors throughout the Caribbean. For more information, please visit https://omholdingsinc.com/.
Forward-Looking Statements
With the exception of the historical information contained in this news release, the matters described herein, may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements preceded by, followed by or that otherwise include the words "believes," "expects," "anticipates," "intends," "projects," "estimates," "plans" and similar expressions or future or conditional verbs such as "will," "should," "would," "may" and "could" are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing. These statements, involve unknown risks and uncertainties that may individually or materially impact the matters discussed herein for a variety of reasons that are outside the control of the company, including, but not limited to, the company's ability to raise sufficient financing to implement its business plan, the impact of the COVID-19 pandemic on the company's business, operations and the economy in general, and the Company's ability to successfully develop and commercial
Mark Vanterpool
Chief Executive Officer
T: 305-901-1497
Email: us.info@omholdingsinc.com
$EMED a pioneer in the development and production of bioelectronic devices designed to relieve chronic, intractable, and acute pain through frequency and electro-modulation, is pleased to announce preliminary unaudited financial performance data for the three months and twelve months ended December 31, 2022.
Preliminary revenue for the twelve months ended Dec 31 was approximately $1.15 million, which represents a total increase in sales of 26.7% on a year-over-year basis.
During the three months ended Dec 31, preliminary revenue increased 79% on a quarterly year-over-year basis and 51% on a sequential quarterly basis.
Matthew Wolfson, Founder and CEO commented, "Q4 was a breakout quarter. We saw topline sales jump in response to further expansion in our brand awareness and sales & marketing performance. Overall, it was our best quarter since we went public and provides strong market feedback that our next-generation R&D and market positioning represents the start of an exciting new chapter for Electromedical. And the path is only going to get more exciting as we get ready to launch our revolutionary Infinity device."
As the Company moves closer to production of the new next-generation flagship device, management plans to offer a special upgrade and exchange program to existing clients, which will be bundled with a lifetime warranty.
The WellnessPro Infinity™ sets a new standard in the bioelectronics and electrotherapy marketplace featuring support for all modalities:
Designed to support*: TENS, Microcurrent, IF, EMS, PEMF, CES, VNS, PNS, COLD Laser, POD Synchronization, IDNA™, Deep Pulse™, cloud access and much more.
Unprecedented accuracy.
Easiest to use electrotherapy device on the market.
New Doctor-Patient Portal for updates and personalized treatments.
Wolfson concluded, "Last year was an ambitious year focused on key R&D objectives that we have met and now we are laying a strong foundation for handling business at a far larger scale. We accomplished everything we set out to accomplish and managed to log impressive sales growth along the way. We are also in the process of expanding consumer resources for purchasing Electromedical products. We have added FSA/HSA purchasing optionality already, and we have some more news coming that could sharply increase customer affordability without impacting our margins, and we look forward to discussing that in further detail very soon."
Management notes that 2023 will see the launch of the WellnessPro Infinity™, continued expansion in its sales team, a strong focus on value-add strategic partnerships, research partnerships and further customer affordability strategies as the Company monetizes its market-leading next-generation drug-free pain therapy technology.
The Company has approximately 10,000 past clients. We expect that we will be successful in encouraging a significant part of our past clients to exchange their old units for the improved Wellness Pro Infinity unit with lifetime warranty. Our development process is progressing and we look forward to providing more updates very soon. We will be in a position to start accepting advance deposits in Q2 for these units, which will greatly enhance the Company's cash position.
About Electromedical Technologies
Headquartered in Scottsdale, Arizona, Electromedical Technologies, Inc. is a commercial stage, FDA cleared, bioelectronic medical device manufacturing company initially focused on the treatment of various chronic, acute, intractable, and post-operative pain conditions. Through University collaboration agreements, the Company is working to develop a comprehensive research program in defining the effects of electro-modulation on the human body. By studying the impacts of electrical fields in cell signaling and effects on virus assembly and immune responses, the Company's goal is to reduce pain and improve overall human wellbeing. The Company's current FDA cleared product indications are for chronic acute post traumatic and post-operative, intractable pain relief.
For more information, please visit www.electromedtech.com
$EMED has approximately 10,000 past clients. We expect that we will be successful in encouraging a significant part of our past clients to exchange their old units for the improved Wellness Pro Infinity unit with lifetime warranty. Our development process is progressing and we look forward to providing more updates very soon. We will be in a position to start accepting advance deposits in Q2 for these units, which will greatly enhance the Company's cash position.
$EMED When it comes to electricity created in the human body, the energy source is chemical and has to do with the composition of the atoms and molecules present. All the elements we take into our bodies, such as oxygen, sodium, potassium, calcium, magnesium etc., have a specific electrical charge. How those molecules are bound together and how they react to other molecules near them is how chemicals create energy. Some of these electrical impulses found naturally in our bodies activate functions needed for healing.
$EMED Preliminary revenue for the twelve months ended Dec 31 was approximately $1.15 million, which represents a total increase in sales of 26.7% on a year-over-year basis.
$AITX News: AITX's Subsidiary, Robotic Assistance Devices, Receives Multiple ROSA Orders from Leading Retail Chain
Detroit, Michigan, April 14, 2023 (GLOBE NEWSWIRE) -- Artificial Intelligence Technology Solutions, Inc., (the "Company") (OTCPK:AITX), a global leader in AI-driven security and productivity solutions along with its wholly owned subsidiary, Robotic Assistance Devices, Inc. (RAD), today announced the successful completion of a pilot at a global big box retailer, which told the Company to expect an opening order for seven ROSA security robots. The order was facilitated by one of RAD's largest national authorized dealers.
The end-user client is a Fortune 100 ranked company with over 1,500 retail locations across the US. These initial ROSAs are slated for deployment at one of the client's retail distribution centers, with the task of detecting and deterring after-hours trespassing, loitering and other security breaches.
"This is the sort of volume business we have been gearing up to support," said Mark Folmer, CPP, FSyI, President of RAD. "Our sales team works diligently to service our dealer network and present the benefits of RAD solutions to end-users like this incredible client. These initial units are just the tip of this giant iceberg of an opportunity."
The Company expects to make additional announcements regarding its authorized dealers' activities and further sales updates.
ROSA is a multiple award-winning, compact, self-contained, portable, security and communication solution that can be deployed in about 15 minutes. Like other RAD solutions, it only requires power as it includes all necessary communications hardware. ROSA's AI-driven security analytics include human, firearm, vehicle detection, license plate recognition, responsive digital signage and audio messaging, and complete integration with RAD's software suite notification and autonomous response library. Two-way communication is optimized for cellular, including live video from ROSA's dual high-resolution, full-color, always-on cameras. RAD has published three Case Studies detailing how ROSA has helped eliminate instances of theft, trespassing and loitering at car rental locations and construction sites across the country.
AITX, through its subsidiary, Robotic Assistance Devices, Inc. (RAD), is redefining the $25 billion (US) security and guarding services industry through its broad lineup of innovative, AI-driven Solutions-as-a-Service business model. RAD solutions are specifically designed to provide cost savings to businesses of between 35%-80% when compared to the industry's existing and costly manned security guarding and monitoring model. RAD delivers this tremendous cost savings via a suite of stationary and mobile robotic solutions that complement, and at times, directly replace the need for human personnel in environments better suited for machines. All RAD technologies, AI-based analytics and software platforms are developed in-house.
RAD has a prospective sales pipeline of over 35 Fortune 500 companies and numerous other client opportunities. RAD expects to continue to attract new business as it converts its existing sales opportunities into deployed clients generating a recurring revenue stream. Each Fortune 500 client has the potential of making numerous reorders over time.
CAUTIONARY DISCLOSURE ABOUT FORWARD-LOOKING STATEMENTS
The information contained in this publication does not constitute an offer to sell or solicit an offer to buy securities of Artificial Intelligence Technology Solutions, Inc. (the "Company"). This publication contains forward-looking statements, which are not guarantees of future performance and may involve subjective judgment and analysis. The information provided herein is believed to be accurate and reliable, however the Company makes no representations or warranties, expressed or implied, as to its accuracy or completeness. The Company has no obligation to provide the recipient with additional updated information. No information in this publication should be interpreted as any indication whatsoever of the Company's future revenues, results of operations, or stock price.
About Artificial Intelligence Technology Solutions (AITX)
AITX is an innovator in the delivery of artificial intelligence-based solutions that empower organizations to gain new insight, solve complex challenges and fuel new business ideas. Through its next-generation robotic product offerings, AITX's RAD, RAD-M and RAD-G companies help organizations streamline operations, increase ROI, and strengthen business. AITX technology improves the simplicity and economics of patrolling and guard services and allows experienced personnel to focus on more strategic tasks. Customers augment the capabilities of existing staff and gain higher levels of situational awareness, all at drastically reduced cost. AITX solutions are well suited for use in multiple industries such as enterprises, government, transportation, critical infrastructure, education, and healthcare. To learn more, visit http://www.aitx.ai, http://www.stevereinharz.com, http://www.radsecurity.com,http://www.radgroup.ai, and http://www.radlightmyway.com, or follow Steve Reinharz on Twitter @SteveReinharz.
###
Steve Reinharz
949-636-7060
@SteveReinharz
$EMED on alert! Electrotherapy is a nerve stimulation therapy via carefully developed electrical impulses mimicking our body signals to help restore damages caused by injuries or accidents. Significant percentage of patients found TENS devices effectively reduced their pain.
https://electromedtech.com/electrotherapy-explained/
$EMED Preliminary revenue for the twelve months ended Dec 31 was approximately $1.15 million, which represents a total increase in sales of 26.7% on a year-over-year basis.
$EMED Electrotherapy is a nerve stimulation therapy via carefully developed electrical impulses mimicking our
body signals to help restore damages caused by injuries or accidents.
Significant percentage of patients found TENS devices effectively reduced their pain.
https://electromedtech.com/electrotherapy-explained/
$ASRE The Company Announces Acquisition of Land for Zanzibar Clean and Renewable Energy Park https://finance.yahoo.com/news/astra-energy-inc-announces-acquisition-142200737.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr via @YahooFinance
$EMED ("Electromedical" or the "Company"), a pioneer in the development and production of bioelectronic devices designed to relieve chronic, intractable, and acute pain through frequency and electro-modulation, is pleased to announce preliminary unaudited financial performance data for the three months and twelve months ended December 31, 2022.
Preliminary revenue for the twelve months ended Dec 31 was approximately $1.15 million, which represents a total increase in sales of 26.7% on a year-over-year basis.
During the three months ended Dec 31, preliminary revenue increased 79% on a quarterly year-over-year basis and 51% on a sequential quarterly basis.
Matthew Wolfson, Founder and CEO commented, "Q4 was a breakout quarter. We saw topline sales jump in response to further expansion in our brand awareness and sales & marketing performance. Overall, it was our best quarter since we went public and provides strong market feedback that our next-generation R&D and market positioning represents the start of an exciting new chapter for Electromedical. And the path is only going to get more exciting as we get ready to launch our revolutionary Infinity device."
As the Company moves closer to production of the new next-generation flagship device, management plans to offer a special upgrade and exchange program to existing clients, which will be bundled with a lifetime warranty.
The WellnessPro Infinity™ sets a new standard in the bioelectronics and electrotherapy marketplace featuring support for all modalities:
Designed to support*: TENS, Microcurrent, IF, EMS, PEMF, CES, VNS, PNS, COLD Laser, POD Synchronization, IDNA™, Deep Pulse™, cloud access and much more.
Unprecedented accuracy.
Easiest to use electrotherapy device on the market.
New Doctor-Patient Portal for updates and personalized treatments.
Wolfson concluded, "Last year was an ambitious year focused on key R&D objectives that we have met and now we are laying a strong foundation for handling business at a far larger scale. We accomplished everything we set out to accomplish and managed to log impressive sales growth along the way. We are also in the process of expanding consumer resources for purchasing Electromedical products. We have added FSA/HSA purchasing optionality already, and we have some more news coming that could sharply increase customer affordability without impacting our margins, and we look forward to discussing that in further detail very soon."
Management notes that 2023 will see the launch of the WellnessPro Infinity™, continued expansion in its sales team, a strong focus on value-add strategic partnerships, research partnerships and further customer affordability strategies as the Company monetizes its market-leading next-generation drug-free pain therapy technology.
The Company has approximately 10,000 past clients. We expect that we will be successful in encouraging a significant part of our past clients to exchange their old units for the improved Wellness Pro Infinity unit with lifetime warranty. Our development process is progressing and we look forward to providing more updates very soon. We will be in a position to start accepting advance deposits in Q2 for these units, which will greatly enhance the Company's cash position.
About Electromedical Technologies
Headquartered in Scottsdale, Arizona, Electromedical Technologies, Inc. is a commercial stage, FDA cleared, bioelectronic medical device manufacturing company initially focused on the treatment of various chronic, acute, intractable, and post-operative pain conditions. Through University collaboration agreements, the Company is working to develop a comprehensive research program in defining the effects of electro-modulation on the human body. By studying the impacts of electrical fields in cell signaling and effects on virus assembly and immune responses, the Company's goal is to reduce pain and improve overall human wellbeing. The Company's current FDA cleared product indications are for chronic acute post traumatic and post-operative, intractable pain relief.
For more information, please visit www.electromedtech.com
$EMED Electromedical Technologies Announces Preliminary Unaudited Revenue for Q4 and FY 2022 and update on operations https://finance.yahoo.com/news/electromedical-technologies-announces-preliminary-unaudited-121900011.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr via @YahooFinance
$EMED Electrotherapy can be used to treat a wide range of of acute and chronic pain.
It also supports healing and recovering and can be used for post-surgical discomfort and to boost your body’s natural recovery properties.
$EMED Preliminary revenue for the twelve months ended Dec 31 was approximately $1.15 million, which represents a total increase in sales of 26.7% on a year-over-year basis.
$EMED preliminary revenue for the twelve months ended Dec 31 was approximately $1.15 million, which represents a total increase in sales of 26.7% on a year-over-year basis.
During the three months ended Dec 31, preliminary revenue increased 79% on a quarterly year-over-year basis and 51% on a sequential quarterly basis.
Matthew Wolfson, Founder and CEO commented, "Q4 was a breakout quarter. We saw topline sales jump in response to further expansion in our brand awareness and sales & marketing performance. Overall, it was our best quarter since we went public and provides strong market feedback that our next-generation R&D and market positioning represents the start of an exciting new chapter for Electromedical. And the path is only going to get more exciting as we get ready to launch our revolutionary Infinity device."
As the Company moves closer to production of the new next-generation flagship device, management plans to offer a special upgrade and exchange program to existing clients, which will be bundled with a lifetime warranty.
The WellnessPro Infinity™ sets a new standard in the bioelectronics and electrotherapy marketplace featuring support for all modalities:
Designed to support*: TENS, Microcurrent, IF, EMS, PEMF, CES, VNS, PNS, COLD Laser, POD Synchronization, IDNA™, Deep Pulse™, cloud access and much more.
Unprecedented accuracy.
Easiest to use electrotherapy device on the market.
New Doctor-Patient Portal for updates and personalized treatments.
Wolfson concluded, "Last year was an ambitious year focused on key R&D objectives that we have met and now we are laying a strong foundation for handling business at a far larger scale. We accomplished everything we set out to accomplish and managed to log impressive sales growth along the way. We are also in the process of expanding consumer resources for purchasing Electromedical products. We have added FSA/HSA purchasing optionality already, and we have some more news coming that could sharply increase customer affordability without impacting our margins, and we look forward to discussing that in further detail very soon."
Management notes that 2023 will see the launch of the WellnessPro Infinity™, continued expansion in its sales team, a strong focus on value-add strategic partnerships, research partnerships and further customer affordability strategies as the Company monetizes its market-leading next-generation drug-free pain therapy technology.
The Company has approximately 10,000 past clients. We expect that we will be successful in encouraging a significant part of our past clients to exchange their old units for the improved Wellness Pro Infinity unit with lifetime warranty. Our development process is progressing and we look forward to providing more updates very soon. We will be in a position to start accepting advance deposits in Q2 for these units, which will greatly enhance the Company's cash position.
About Electromedical Technologies
Headquartered in Scottsdale, Arizona, Electromedical Technologies, Inc. is a commercial stage, FDA cleared, bioelectronic medical device manufacturing company initially focused on the treatment of various chronic, acute, intractable, and post-operative pain conditions. Through University collaboration agreements, the Company is working to develop a comprehensive research program in defining the effects of electro-modulation on the human body. By studying the impacts of electrical fields in cell signaling and effects on virus assembly and immune responses, the Company's goal is to reduce pain and improve overall human wellbeing. The Company's current FDA cleared product indications are for chronic acute post traumatic and post-operative, intractable pain relief.
For more information, please visit www.electromedtech.com
$EMED Electricity enables information to circulate in the body, electrotherapy manipulates a specific part of the information by pulsating electrical waves interfering with the transmission of pain signals.
Our nervous system is composed of our brain and our spinal cord, which combine to form the central nervous system; and our sensory and motor nerves, which form the peripheral nervous system. Nerves send information about what is happening in our environment to the brain via the spinal cord. The brain then sends information back to our nerves, helping us to perform actions in response. By treating specific body areas and varying frequency, wavelength and intensity applied, electrotherapy devices can manipulate impulses and target actions to alleviate pain or they can disrupt pain signals.
$EMED When it comes to electricity created in the human body, the energy source is chemical and has to do with the composition of the atoms and molecules present. All the elements we take into our bodies, such as oxygen, sodium, potassium, calcium, magnesium etc., have a specific electrical charge. How those molecules are bound together and how they react to other molecules near them is how chemicals create energy. Some of these electrical impulses found naturally in our bodies activate functions needed for healing.
$EMED Electrotherapy is a nerve stimulation therapy via carefully developed electrical impulses mimicking our
body signals to help restore damages caused by injuries or accidents.
Significant percentage of patients found TENS devices effectively reduced their pain.
https://electromedtech.com/electrotherapy-explained/
$EMED as the Company moves closer to production of the new next-generation flagship device, management plans to offer a special upgrade and exchange program to existing clients, which will be bundled with a lifetime warranty.
The WellnessPro Infinity™ sets a new standard in the bioelectronics and electrotherapy marketplace featuring support for all modalities:
Designed to support*: TENS, Microcurrent, IF, EMS, PEMF, CES, VNS, PNS, COLD Laser, POD Synchronization, IDNA™, Deep Pulse™, cloud access and much more.
Unprecedented accuracy.
Easiest to use electrotherapy device on the market.
New Doctor-Patient Portal for updates and personalized treatments.
Wolfson concluded, "Last year was an ambitious year focused on key R&D objectives that we have met and now we are laying a strong foundation for handling business at a far larger scale. We accomplished everything we set out to accomplish and managed to log impressive sales growth along the way. We are also in the process of expanding consumer resources for purchasing Electromedical products. We have added FSA/HSA purchasing optionality already, and we have some more news coming that could sharply increase customer affordability without impacting our margins, and we look forward to discussing that in further detail very soon."
Management notes that 2023 will see the launch of the WellnessPro Infinity™, continued expansion in its sales team, a strong focus on value-add strategic partnerships, research partnerships and further customer affordability strategies as the Company monetizes its market-leading next-generation drug-free pain therapy technology.
The Company has approximately 10,000 past clients. We expect that we will be successful in encouraging a significant part of our past clients to exchange their old units for the improved Wellness Pro Infinity unit with lifetime warranty. Our development process is progressing and we look forward to providing more updates very soon. We will be in a position to start accepting advance deposits in Q2 for these units, which will greatly enhance the Company's cash position.
About Electromedical Technologies
Headquartered in Scottsdale, Arizona, Electromedical Technologies, Inc. is a commercial stage, FDA cleared, bioelectronic medical device manufacturing company initially focused on the treatment of various chronic, acute, intractable, and post-operative pain conditions. Through University collaboration agreements, the Company is working to develop a comprehensive research program in defining the effects of electro-modulation on the human body. By studying the impacts of electrical fields in cell signaling and effects on virus assembly and immune responses, the Company's goal is to reduce pain and improve overall human wellbeing. The Company's current FDA cleared product indications are for chronic acute post traumatic and post-operative, intractable pain relief.
For more information, please visit www.electromedtech.com
Followers
|
525
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
45886
|
Created
|
02/21/10
|
Type
|
Free
|
Moderator MaxPowerLove$Ihub | |||
Assistants mick Ask$lapper k124Inv RoadRunner3 |
Welcome!
Sad =( Not Funny! But it's True!
Remember, The OTC Market is like Vegas! Treat trading & investing in every penny stocks like Casino gambling!
Check out some of our picks & results in the past:
Recent Plays:
Le2dynasty: Alerted for CBYI in late March @ the point when the stock was at no bid. A few weeks later the PPS reached .0004s (400% gain)
Le2dynasty: Alerted for GRPS (together with KGRI, CBYI) @ .0001s on May 17th...On May 23rd the PPS touched .0012s (1,200% gain)
Le2dynasty: Alerted for CBYI @ .0001s on May 23rd -- early morning & within a few hours, the PPS reached .0003s with mega trading volume-- (71 mil. total trading vol. with 99% buyin' vol.) (300% gain)
Le2dynasty: Alerted for CBYI @ .0002s on May 24rd -- early morning & immediately, the PPS reached .0004s with mega trading volume -- (more than 100 mil. total trading vol. CBYI was the top in top trading vol. on this day) (100% gain)
Le2dynasty: Alerted for EMLL @ .0002s on July 2nd -- early morning & the PPS reached .0004s with mega trading volume -- (more than 260 mil. total trading vol. EMLL became the top in top trading vol. & top in breakout board on this day) (50% gain)
Le2dynasty: Alerted for HIRU @ .0001s on July 3rd & on July 9, HIRU reached .0006s with mega trading volume (600% gain)
Le2dynasty: Alerted for IMDS @.0005s on July 9 @ the pt. when the total trading vol. is below 80 mil. Within 50 minutes later, the PPS reached .0009s, with more than 245 mil. total trading vol. (80% gain) in less than 1 hr. On July 10th another alert was sent out to remind traders/investors & on July 12th, the PPS reached .0026s..that is more than (500% gain) since July 9 alert.
Le2dynasty: Alerted for NVAE in early moring @ the pt. when the stock was @ no bid. PPS then reached .0003s (200% again) with a mega trading vol. (end the trading day with more than 230 mil total trading vol.). Unfortunately, the the stock dropped back to .0001 at closing.
BurntOrang3: : 400-500% gains off of DRGI after the alert
BurntOrang3: : Over 100% gains after my AUCI alert
**** Attention: Mods, Please don't edit the ibox w/o asking me first, b/c there are some kind of coding problems here ...and the IH Greeks ...Especially IH Greek (Dave) had spent a lot of time fixing this. Thank you Dave and thank all the mods here as well ****
Our Associates:
TheKingPennyStock
Daily 000X Plays
Monster Day Traders
Pinky With Potential!
BOTTOM PLAYS! CHART TECH! RESEARCH! STRATEGIES!
"A Dawgg"
Billionaire Boys Club Member Forum (BBCMF)
THE WALL STREET CLUB
$THE WAVE
THE BLUE EXCHANGE
ALERTS, CHARTS, & HOT STOCKS
Momentum Players
Momentum Runners
MOMO'S BREAKOUT BOARD
STOCKGOODIES PLAYS OF THE WEEK
Welcome To The Zoo
~~~TEFFY''S~~~HOT~~~PROFILED~~~PICKS~~~
Another Winning Trade
CASH COW
EZ Traders Forum
NO BRAINERS
StocksDiva Bio Bin
Pinto Beans and Money Making Stock Picks
PINKSHEET Breakout Board!!!
Picks For Every Play
Penny Stock Millionaire
The Van Scan
UNDERVALUED PENNY STOCKS
The Penny Stock Grow Room
Wowza board
Disclaimer: We are not investment advisors. We recommend investors to do their own due diligence. Never invest in any stock unless you can afford to lose your entire investment. Opinions expressed on this board are only opinions.
PER IHUB MGMT |
02-07-2021
DISCLAIMER: ONLY FOR MICK
https://investorshub.advfn.com/boards/profilea.aspx?user=1012
*The Board Monitor and herewithin , are not licensed brokers and assume NO responsibility for actions,
investments,decisions, or messages posted on this forum.
CONTENT ON THIS FORUM SHOULD NOT BE CONSIDERED ADVISORY NOR SOLICITATION
AUTHORS MAY HAVE BUYS OR SELLS WITH THE COMPANIES MENTIONED IN TRADING POSTERS SHOULD DUE DILIGENT BUYING OR SELLING.
ALL POSTING SHOULD BE CONSIDERED FOR INFORMATION ONLY. WE DO NOT RECOMMEND ANYONE BUY OR SELL ANY SECURITIES POSTED HEREWITHIN.
ANY trade entered into risks the possibility of losing the funds invested.
• There are no guarantees when buying or selling any security.Any
Posts Today
|
0
|
Posts (Total)
|
45886
|
Posters
|
|
Moderator
|
|
Assistants
|
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |